Biomarker for Glycogen Storage Diseases (BioGlycogen)

Withdrawn

• Conditions: Glycogen Storage Disease Type I; Glycogen Storage Disease Type IV; Glycogen Storage Disease Type VII; Fructose Metabolism, Inborn Errors; Glycogen Storage Disease Type V; Glycogen Storage Disease Type II; Glycogen Storage Disease Type III; Glycogen Storage Disease; Glycogen Storage Disease Type VI; Glycogen Storage Disease Type VIII

• Registration Number: NCT02385162
• Lead Sponsor: CENTOGENE GmbH Rostock

Brief Summary

Development of a new MS-based biomarker for the early and sensitive diagnosis of Glycogen Storage Diseases from plasma. Testing for clinical robustness, specificity and long-term stability of the biomarker.

Detailed Description

Glycogen storage diseases (GSDs) are a group of inherited genetic disorders that cause glycogen to be improperly stored in the body. People with glycogen storage diseases have a buildup of abnormal amounts or types of glycogen in their tissues.

The main types of glycogen storage diseases are categorized by number and name. They include:

People with GSD I may have episodes of low blood sugar (hypoglycemia), usually during periods of fasting, due to the ability to store glycogen but inability to properly release it. People with GSD I typically develop an enlarged liver (hepatomegaly) from the storage of glycogen. Elevations in liver function enzymes, blood fat and cholesterol levels, lactic acid, and uric acid also occur. Additional features of GSD I can include decreased bone density, poor growth, kidney disease, liver adenomas, and delayed puberty. Treatment primarily consists of dietary management to maintain normal blood glucose levels and prevent hypoglycemia. GSD I is further divided into subtypes. GSD Type Ia is caused by a deficiency of glucose-6-phosphatase (G6Pase) primarily in the liver, and GSD Type Ib is caused by a deficiency of glucose-6-phosphate translocase. Many of the symptoms are similar, especially early in life. However, some people with Type Ib are more prone to infections given a weaker immune system. GSD I is caused by a non-working change in either the G6PC gene or the SLC37A4 gene, causing the deficiency of the particular enzyme. GSD I follows autosomal recessive inheritance.

Glycogen Storage Disease Type II \[also known as Pompe disease, Acid Maltase Deficiency, Glycogenosis Type II, Acid alpha-Glucosidase Deficiency, Lysosomal alpha-Glucosidase Deficiency\] Pompe disease is an inherited and often fatal disorder caused by the deficiency of acid alpha-glucosidase (GAA), an enzyme needed to breakdown glycogen (sugar that is stored for energy) in specialized structures in the body, called lysosomes. Patients with Pompe disease have little or no GAA enzyme activity and cannot breakdown glycogen. The excess glycogen accumulates and is stored in the heart, skeletal muscle and other tissues, causing the progressive symptoms of Pompe disease.Glycogen Storage Disease Type III \[also known as Cori disease, Forbes disease, Debrancher enzyme deficiency, Limit Dextrinosis\]

Study Timeline

• Study First Submitted: 2015-03-02
• Study First Submitted QC: 2015-03-10
• Study First Posted: 2015-03-11
• Study Start: 2018-08-20
• Primary Completion: 2021-02-28
• Study Completion: 2021-02-28
• Status Verified: 2023-02
• Last Update Submitted: 2023-02-09
• Last Update Posted: 2023-02-13

Recruitment & Eligibility

• Status: WITHDRAWN
• Sex: All
• Target Recruitment: Not specified

Inclusion Criteria

• Informed consent will be obtained from the parents before any study related procedures.
• Patients of both genders older than 2 month
• The patient has a diagnosis of glycogen storage disease or a high-grade suspicion for glycogen storage disease

High-grade suspicion present, if one or more inclusion criteria are valid:

• Positive family anamnesis for glycogen storage disease
• Hypoglycemia
• Growth retardation: short stature, skeletal myopathy
• Hepatomegaly, Splenomegaly
• Myopathy with muscle weakness
• cardiomyopathy

Exclusion Criteria

• No Informed consent from the parents before any study related procedures
• Patients of both genders younger than 2 month
• No diagnosis of glycogen storage disease or no valid criteria for high-grade suspicion of glycogen storage disease

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Development of a new MS-based biomarker for the early and sensitive diagnosis of Glycogen storage disease using the technique of Mass-spectometry 7,5 ml EDTA blood, saliva tube and a dry blood spot filter card	24 months	New methods, like mass-spectrometry give a good chance to characterize specific metabolic alterations in the blood of affected patients that allow diagnosing in the future the disease earlier, with a higher sensitivity and specificity.

Secondary Outcome Measures

Name	Time	Method
Testing for clinical robustness, specificity and long-term stability of the biomarker	36 months	the goal of the study to identify and validate a new biochemical marker from the blood of the affected patients helping to benefit other patients by an early diagnose and thereby with an earlier treatment.

Trial Locations

Locations (4)

Amrita Institute of Medical Sciences & Research Centre; 🇮🇳 Cochin, Kerala, India

Centogene AG; 🇩🇪 Rostock, Germany

Navi Mumbai Institute of Research In Mental And Neurological Handicap (NIRMAN); 🇮🇳 Mumbai, India

Lady Ridgeway Hospital for Children; 🇱🇰 Colombo 8, Sri Lanka